Recommended Articles
Fundraising

XRlabs Raises $8.4M Seed to Build the AI Layer for Every Operating Room

By Angeled · October 20, 2026 · Fundraising
XRlabs Raises $8.4M Seed to Build the AI Layer for Every Operating Room
XRlabs Raises $8.4M Seed to Build the AI Layer for Every Operating Room

XRlabs, the London-based "Surgical Intelligence" company, has raised $8.4 million (€7.48 million) in seed funding led by Playground Global, with participation from London-based healthtech investor Eka Ventures. Announced via Business Wire on October 19, 2026, the round will accelerate development and clinical deployment of XRlabs' device-agnostic platform, which embeds real-time AI directly into the operating room.

The deal at a glance

Alongside the raise, XRlabs announced a heavyweight board appointment: Omar Ishrak, who led Medtronic as chairman and CEO from 2011 to 2020 and previously chaired Intel's board (he also serves on the boards of Amgen and Cleveland Clinic), has joined as chair of the board. The capital will fund engineering and clinical team expansion, regulatory pathways across the UK, Europe, and the US, and a growing clinical evidence base across partner institutions.

What XRlabs does

Founded in 2024 by practicing neurosurgeon Dr. Ali Haddad, XRlabs is headquartered in London at the London Institute for Healthcare Engineering, with a second office in Palo Alto. The company develops modular, device-agnostic software that sits as an external AI layer across the surgical systems hospitals already own. Using computer vision and deep learning, it turns live surgical video into real-time intelligence at the point of care — an AI "co-pilot" for the surgical team that enhances visualization, situational awareness, and workflow.

The positioning is the product: rather than asking hospitals to replace equipment, XRlabs makes the systems they already own work together intelligently. The platform runs on 4K 3D surgical scopes (including the Olympus ORBEYE exoscope), interfaces with neuronavigation systems, and fuses live surgical video, navigation telemetry, and pre-operative CT and MRI imaging into a single real-time, anatomy-aware view of the operation.

XRlabs offers two core products:

  • XRlabs SIM — a patient-specific planning and rehearsal tool that converts standard CT and MRI scans into interactive 3D models (digital twins) of a patient's anatomy, letting surgeons visualize and rehearse procedures in an extended-reality environment
  • SurgicalOS — the intraoperative intelligence layer that brings the SIM digital twin into the live operative view

Clinical traction

The company reports its platform has been used across more than 100 surgical cases on three continents, following a run of landmark clinical firsts. In March 2026, XRlabs reported using its AI system with an ORBEYE 4K 3D exoscope during a neurosurgical procedure at Lenox Hill Hospital in New York. It also participated in the development of AI-designed, patient-specific implants used in the separation of craniopagus twins, working with UK charity Gemini Untwined.

The "Android moment" thesis

As one October 19 analysis put it, XRlabs is betting on an "Android moment" in the operating room: not reinventing imaging devices, but getting existing Olympus scopes, navigation systems, and image-archiving systems to work together through a software layer. That positioning is commercially lighter — no hardware manufacturing, no rip-and-replace sales cycles — but it is no simpler when it comes to clinical validation and regulation. The regulatory pathway for AI that influences live surgery is genuinely hard, which is precisely why a former Medtronic chairman on the board and a seed round earmarked for UK/EU/US regulatory work matters.

Playground Global general partner Bruce Leak framed the founder-fit thesis: "The best physical AI companies come from people who've experienced a problem in their field firsthand and have the deep expertise to know how to fix it." Dr. Haddad's own formulation: "Our conviction is that the operating room is the next frontier for physical AI. Surgery generates extraordinary data, yet almost none of it becomes intelligence in the moments that matter most."

Why it matters for founders

XRlabs demonstrates the device-agnostic wedge in healthtech: sell software that makes existing capital equipment smarter, and you sidestep the hospital's hardest procurement objection ("we just bought a $2M system"). Founders in regulated domains should study the sequencing — clinical firsts and a 100-case evidence base before the seed raise, a regulatory-first use of funds, and a board chair who has personally navigated Medtronic-scale device regulation. In medtech, credibility is the go-to-market, and XRlabs is buying it in exactly the right order.

Why it matters for investors

Surgical AI is a frontier where data moats compound: every case generates labeled, anatomy-aware video that improves the models. Playground Global's DeepTech focus and Ishrak's appointment signal that sophisticated investors see "physical AI" in the OR as a genuine infrastructure layer, not a gadget. The risks are regulatory timelines (three jurisdictions at once) and the need for randomized clinical evidence to convert pilot deployments into standard-of-care contracts — but the €7.48M seed is sized for exactly that multi-year validation grind.

Angeled.com connects founders with investors.

Sources: MobiHealthNews (Oct 19, 2026), EU-Startups, Business Wire via Morningstar

Read Next